Victrix Computational Chemistry and Medicinal Chemistry Consultancy
Contact us
  • Home
  • Philosophy
  • Services
  • Our Clients
  • Contact
  • About
    • Press Releases
  • Victrix Sounds Off
  • Blog

Part 3: In which a computational chemist and drug hunter, imbued with Leibnizian optimism proposes a way in which the pharmaceutical industry may be saved from it's self

6/19/2013

2 Comments

 
Picture
Leibniz argued we live in the best of all possible worlds.  I realize that looking at what goes on around us causes pause at this statement, but ask yourself, what percentage of our problems are caused by human frailty and not an inherent conditional aspect of the universe as a whole.  I'll stop the philosophical meanderings now, and switch to my plan to fix the pharmaceutical industry.

First we must agree on some points.  Number one is that the pharmaceutical industry, while a business which exists to make money, is a very different business than others.  Why discover drugs when you could make tyres, or tacos? Presumably because you want to apply to scientific training to something that will help humanity in some small way. Consequently, point number two follows. Drugs are not tacos.  Creating a demand for drugs is inherently not the point of the business. Drugs that make a significant difference in peoples lives create their own market. Lipitor became a huge seller before all the massive market-creating direct to consumer advertising started.  Therefore we should strive to create drugs that solve problems that exist, not find a use for a drug that your have.

Point three is that all of the major blockbuster drugs were created before the merger mania.  it is impossible to be innovative in a crushing bureaucracy.  Just ask any of your Russian colleagues about being innovative in the Soviet Union. Consequently, the mergers need to be undone. Pfizer, Novartis, etc.  need to be broken up into smaller companies where a drug that produces $350 - $400 million in revenue would be significant enough to make a difference.  

A corollary to point three is that is drugs are not tacos, you can't let managment come from the same business background that is created in most business schools.  Research can not be viewed as an expense.  It costs about a billion dollars and takes ten to fifteen years to create a functioning research group.  Cutting, or shutting down a research site is equivalent to shooting your dairy cows for meat, or eating the seed corn. The steak may taste good, but when you realize you need milk, you will need to go buy cows that you really should already have.  

Pfizer has admitted that it can't do research and is looking around for innovative products from small companies that employ the scientists that Pfizer fired when they shut down all the research sites that they acquired in the mergers.  To quote a Pogo comic strip, "we have met the enemy and they are us!".

The problems in the pharmaceutical industry can be solved by reversing the results of merger mania.  Also require that the shut down facilities be turned over to a non-profit foundation (Hey Bill and Melinda Gates, I'm talking to you)  where companies can be incubated for free for a period of time.  Be very loose on the criteria to get in and get started and then do a two year review and be very harsh on the criteria to stay. Let the non-profit be involved in getting funding and make sure it has enough clout to keep the Harvard MBAs out. Let them then license the products out to recoup the costs.  Core functionality like scale-up, Preclinical and clinical research can be centralized so the scientists can focus on research. 

we have to get small or all we will have are 3rd generation Viagras and more invented conditions like "low testosterone".

I welcome feedback. Contact me, follow on twitter (@VictrixCMC).  Particularly if you are Bill Gates. 


2 Comments
Rodney
6/20/2013 12:47:26 am

I agree completely, and am shocked that there is ANY business where 400 million in revenue is not enough to 'make a difference' (perhaps I misread you?)

To some extent is this not what drug companies are already doing as they form more and more partnerships with small independent university labs? It almost reminds one of the athlete-corporate sponsor model. You pay them to do their own thing, and then your label gets their win.

Reply
Adam Kallel link
6/21/2013 11:10:41 am

Hi Rodney,

Surprisingly enough these $400-600 million per annum in revenue drugs fall below the radar screen of the behemoths that merger mania have created.

Sadly many good drugs remain undeveloped because market assessment has deemed the profit too small to warrant the enormous cost of development. Sad, but true. They want billion dollar molecules, not the least because 9/10 clinical candidates fail, and they need to recoup the cost of development (1 billion +) for the failures as well as the successes.

Reply



Leave a Reply.

    Adam Kallel Ph. D.

    Our CSO sounds off about drug discovery, computational chemistry and history

    Archives

    March 2014
    January 2014
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013

    Categories

    All
    Ageing
    Amphetamine
    Anti-virals
    Biography
    Broken Society
    Caffeine
    Cancer
    Cd26
    Cluster Headache
    Colic
    Collaboration
    Corona Virus
    Danger Danger
    Depression
    Drug Discovery
    Drug Resistence
    Economy Of Scale
    Electron Microscopy
    Emergent Infectious Disease
    Encephalitis Lethargica
    Global Epidemiology
    Goal Setting
    HCoV-EMC
    Hiring
    Incorrect Pathologizing
    Incretin
    Influenza
    Jobs
    Me
    Merck
    Mergers
    Metabolic Disease
    Migraine
    Nerd
    Neurotransmiters
    Open Positions
    Over Prescription
    Overwork
    Pharma
    Pharmaceutical Industry
    Restructuring
    Stimulants
    Telomerase
    Tuberculosis
    Viral Replication
    Virus

    RSS Feed

    comments powered by Disqus
    View my profile on LinkedIn